Guidance marks the regulatory body’s first on artificial intelligence applications in drug and biological product development.
Beyond the Ordinary Beyond the Obvious
Beyond the Ordinary Beyond the Obvious
Guidance marks the regulatory body’s first on artificial intelligence applications in drug and biological product development.
